Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects (0000-069)

Phase 1 Completed 37 enrolled Merck Sharp & Dohme LLC

RandomizedCrossoverDouble-blindTreatment

Summary

This study will evaluate whether chronic dosing with Niaspan™ increases reverse cholesterol transport, high-density lipoprotein cholesterol (HDL-C) levels, and fecal excretion of cholesterol.

Timeline

Start: 2010-02
Primary completion: 2010-08
Completion: 2010-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Niacin	Small molecule	—	—

Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects (0000-069)

Summary

Timeline

Drugs

Indications